399 Views

Development, Regulatory & Outcomes (DRO) Network

Wednesday, January 12, 2022

12:00 PM – 1:00 PM ET

Network and Community Chair(s)

Jing Liu, PhD

Senior Director, Clinical Pharmacology
Pfizer

Network and Community Speaker(s)

Brian W. Corrigan, PhD

Global Head Clinical Pharmacology
Pfizer
Dan Hartman, MD

Director, Integrated Development; Global Health
Bill & Melinda Gates Foundation
Nita A. Limdi, PharmD, PhD

Professor
University of Alabama at Birmingham
Rajanikanth Madabushi, PhD

Associate Director, Guidance and Scientific Policy
US Food and Drug Administration

Session Description

The Development, Regulatory & Outcomes (DRO) Network meeting will begin with a business meeting including an overview of DRO, highlights of the year, a call for volunteers, Network leadership transition, and vision for the Network's future. The remaining time will be a scientific session of interest to broader ASCPT members on Enhancing Diversity in Clinical Trials: How Clinical Pharmacology and Translational Science Can Help. Representatives from different sectors will share their perspectives by providing brief responses to a few questions surveyed by the DRO Network. Following the interviews, a live Q&A will be held for the audience and the panelists.

Learning Objectives

1. The importance of enhancing clinical trial diversity.

2. How to improve the clinical trial diversity using innovative clinical pharmacology, therapeutic and translational science approaches.

Session Schedule

12:00 PM - 12:10 PM ET
Welcome, Agenda, and DRO Annual Review
Jing Liu, PhD

12:10 PM - 12:15 PM ET
Network Leadership Transition and Vision for DRO’s Future
Jing Liu, PhD

12:15 PM - 12:45 PM ET
Enhancing Diversity in Clinical Trials: How Clinical Pharmacology and Translational Science Can Help
Brian Corrigan, PhD, Dan Hartman, MD, Nita Limdi, PharmD, PhD, and Rajanikanth Madabushi, PhD

12:45 PM - 1:00 PM ET
Live Q&A, Discussion, and Closing Comments
All Speakers